Scholarlink

<p>This study examined trends in radiotherapy use among older patients with early-stage non-small cell lung cancer (NSCLC) in Japan. Using hospital-based cancer registry data (2013–2022), we analyzed 295,662 patients aged ≥ 65 years with epithelial lung tumors (clinical Tis–T2N0M0), excluding those with poorly differentiated endocrine carcinoma or missing treatment data. Overall, 80% underwent surgery, 11% received radiotherapy, and 9% received other management. Radiotherapy use increased from 10.5% in 2013 to 12.8% in 2022 (age- and sex-standardized increase of + 1.2% points). Logistic regression showed increased odds of radiotherapy use in the later period across subgroups according to age, sex, clinical T category, and facility volume, except among patients aged 75–84 years and those treated at high-volume facilities. From 2013 to 2022, radiotherapy use changed by + 1.7, + 0.2, and + 4.5% points among patients aged 65–74, 75–84, and ≥ 85 years, reaching 6.2%, 14.8%, and 35.5%, respectively. Surgery use changed by − 2.1, + 1.3, and − 3.2% points, with values of 89.6%, 76.3%, and 32.8%, respectively. Radiotherapy use increased only modestly, with variation across age groups. Over 30% of patients aged ≥ 85 years underwent surgery, indicating the need to clarify the roles of surgery and radiotherapy in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nationwide trends in radiotherapy use among older patients with early-stage non-small cell lung cancer in Japan, 2013–2022

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Toshiki Ikawa,
  • Kayo Nakata,
  • Kenji Kishimoto,
  • Toshitaka Morishima,
  • Naoyuki Kanayama,
  • Masahiro Morimoto,
  • Koji Konishi,
  • Isao Miyashiro

摘要

This study examined trends in radiotherapy use among older patients with early-stage non-small cell lung cancer (NSCLC) in Japan. Using hospital-based cancer registry data (2013–2022), we analyzed 295,662 patients aged ≥ 65 years with epithelial lung tumors (clinical Tis–T2N0M0), excluding those with poorly differentiated endocrine carcinoma or missing treatment data. Overall, 80% underwent surgery, 11% received radiotherapy, and 9% received other management. Radiotherapy use increased from 10.5% in 2013 to 12.8% in 2022 (age- and sex-standardized increase of + 1.2% points). Logistic regression showed increased odds of radiotherapy use in the later period across subgroups according to age, sex, clinical T category, and facility volume, except among patients aged 75–84 years and those treated at high-volume facilities. From 2013 to 2022, radiotherapy use changed by + 1.7, + 0.2, and + 4.5% points among patients aged 65–74, 75–84, and ≥ 85 years, reaching 6.2%, 14.8%, and 35.5%, respectively. Surgery use changed by − 2.1, + 1.3, and − 3.2% points, with values of 89.6%, 76.3%, and 32.8%, respectively. Radiotherapy use increased only modestly, with variation across age groups. Over 30% of patients aged ≥ 85 years underwent surgery, indicating the need to clarify the roles of surgery and radiotherapy in this population.